Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: sunami k. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Nishimori H, et al. Among authors: sunami k. Int J Hematol. 2009 Apr;89(3):326-331. doi: 10.1007/s12185-009-0259-8. Epub 2009 Mar 27. Int J Hematol. 2009. PMID: 19326060
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, Mizuno I, Tamaki S, Kamimura T, Tsuda H, Gondo H, Hino N, Shimazaki C, Miyata A, Tajima F, Takemoto Y, Miwa A, Chou T, Harada M. Sunami K, et al. Int J Hematol. 2009 Dec;90(5):635-642. doi: 10.1007/s12185-009-0445-8. Epub 2009 Nov 21. Int J Hematol. 2009. PMID: 19936876 Clinical Trial.
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: sunami k. Int J Hematol. 2010 Oct;92(3):503-9. doi: 10.1007/s12185-010-0673-y. Epub 2010 Sep 8. Int J Hematol. 2010. PMID: 20824401 Clinical Trial.
Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.
Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, Hanada S, Sunami K, Inoue N, Sawamura M, Yoshida S, Shimomura T, Kitano K, Kojima Y, Horibe K, Nagai H. Kihara R, et al. Among authors: sunami k. Int J Hematol. 2013 Jan;97(1):98-102. doi: 10.1007/s12185-012-1243-2. Epub 2012 Dec 15. Int J Hematol. 2013. PMID: 23243003
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M, Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: sunami k. Int J Hematol. 2013 Aug;98(2):179-85. doi: 10.1007/s12185-013-1389-6. Epub 2013 Jul 6. Int J Hematol. 2013. PMID: 23832805 Clinical Trial.
341 results